Skip to main content

Table 17 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Netherlands

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
3L-VAS
 Improved 0.80 0.90 0.10 (0.02 to 0.17) 0.81* 13 69
 No change 0.85 0.87 0.01 (− 0.02 to 0.06) 0.12 32 41
 Worsened 0.75 0.74 − 0.01 (− 0.12 to 0.09) − 0.05 18 28
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
5L-VAS
 Improved 0.75 0.87 0.11 (0.02 to 0.20) 0.78 13 62
 No change 0.82 0.85 0.03 (− 0.01 to 0.06) 0.16 32 38
 Worsened 0.73 0.69 − 0.04 (− 0.14 to 0.06) − 0.14 18 39
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large. *p < 0.05